Combining targeted therapies for ovarian cancer with ARID1A mutations
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer
This study is looking at new ways to treat ovarian cancer that has a specific gene mutation called ARID1A, by using special medicines that target important proteins in the cancer cells, and it hopes to find better treatments for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10640147 on NIH RePORTER |
What this research studies
This research focuses on developing new treatment strategies for ovarian cancers that have mutations in the ARID1A gene, which are common in certain types of ovarian cancer. The approach involves using small molecule inhibitors to target specific proteins, EZH2 and HDAC6, that are crucial for the survival of cancer cells with these mutations. By understanding how these inhibitors work together, the research aims to create a more effective treatment that could improve outcomes for patients with ARID1A-mutated ovarian cancer. Patients may be involved in trials testing these new combination therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ovarian clear cell carcinoma or ovarian endometrioid carcinoma who have ARID1A mutations.
Not a fit: Patients without ARID1A mutations or those with other types of ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with ARID1A-mutated ovarian cancers, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results with synthetic lethality approaches in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Zhang, Rugang — University of Tx Md Anderson Can Ctr
- Study coordinator: Zhang, Rugang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.